Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 12 , Pages 1527-1532, December 2006

Pharmacological Management of a Youth With ADHD and a Seizure Disorder

Dr. Kratochvil is with the Department of Psychiatry, University of Nebraska Medical Center, Omaha; Dr. Gonzalez-Heydrich is with Children's Hospital Boston and Harvard Medical School; Dr. Weiss is with the Division of Child Psychiatry and Drs. Connolly and Wambera are with the Department of Neurology, Children's and Women's Health Centre, Vancouver, BC, Canada; Dr. Jan is with the Department of Paediatrics, University of British Columbia, Vancouver; Dr. Plioplys is with Northwestern University and Children's Memorial Hospital, Chicago; and Dr. Dunn is with the Department of Psychiatry and Neurology, Indiana University School of Medicine, Indianapolis

Accepted 26 July 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. While it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil has received grant support from and is a consultant to and/or member of the speakers' bureaus of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Dunn has received grant support from and is a consultant to and/or member of the speakers' bureau of Eli Lilly, AstraZeneca, Otsuka, and McNeil. Dr. Gonzalez-Heydrich has received grant support from and is a consultant to and/or member of the speakers' bureaus of Pfizer, Abbott Laboratories, Cyberonics, Janssen Pharmaceutical Research Foundation, McNeil Consumer and Specialty Pharmaceuticals, Novartis, GlaxoSmithKline, and Eli Lilly. Dr. Weiss is a consultant to and serves on the advisory boards of Eli Lilly, Janssen, Shire, Purdue, Circa Dia, Novartis, and Cephalon; is a speaker for Eli Lilly, Janssen, Shire, Novartis, and Cephalon; and has received research support from Eli Lilly, Janssen, Shire, Purdue, and Circa Dia. Dr. Plioplys is a member of the speakers' bureau of Novartis. Dr. Jan has received grant support from and is a consultant to and/or member of the speakers' bureau of Circa Dia and Telethon. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)61811-6

doi:10.1097/01.chi.0000240836.71361.39

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 12 , Pages 1527-1532, December 2006

Article Tools